OncoDNA, the cancer therapy company
Who are we?
OncoDNA is a leading Belgian multinational company in Europe, specialized in precision medicine in Oncology and other genetic diseases . In 2012, OncoDNA was founded with the idea of making precision medicine in oncology a reality. In 2015, OncoDNA acquired BioSequence, becoming its subsidiary in Spain and Portugal, located in Valencia.
In just one decade, the OncoDNA Group, in addition to BioSequence in Spain, has incorporated another large company in France, IntegraGen, and has approximately 115 employees in nine different countries, works with 35 distributors, and collaborates with several accredited laboratories in both Europe and the United States.
The OncoDNA Group is comprised of a group of individuals whose main goal is to find useful and individualized solutions to better understand the complexity of genetic diseases.
In addition, we collect, explore, and interpret data that may be useful for clinical trials, research projects, or decisive in clinical decision-making, with a single goal: to provide patients with the best personalized treatment to improve their condition and thus enhance their quality of life.
What is our mission?
Our primary mission is to provide medical professionals, biopharmaceutical companies, and researchers with all the tools and information they need to put precision medicine into practice.
Thanks to this goal, we have formed a chain in which all our collaborators participate, from the research and development of new drugs to the treatment and follow-up of patients.
What do we offer?
We have biomarker tests (OncoDEEP, OncoSELECT, OncoFOLLOW, etc.) that can help with both selecting the most appropriate treatment for a specific type of cancer and monitoring it. They can be used for both solid and liquid biopsy analysis, and through ultrasequencing technology and advanced bioinformatics, we can obtain useful data and use it to develop new, more effective diagnostic and treatment strategies.
Also, because IntegraGen is a leader in ultrasequencing and specializes primarily in cancer genomics and genetic diseases, we can offer sequencing services ranging from whole genome or exome RNA Seq to specific or customized panels.
We provide access to secure online bioinformatics analysis and interpretation platforms (OncoKDM, OncoSHARE, and Mercury) that help analyze sequencing data more quickly and associate it with the latest therapies, build customized reports, and communicate them with the healthcare community.
OncoDEEP, What is it?
OncoDEEP® is a biomarker test that helps guide oncologists in the treatment of advanced solid tumors, as well as pediatric glioblastomas. OncoDEEP helps expand molecular knowledge to discover the best treatment strategy for the patient. The test is indicated for the diagnosis of rare tumors, as well as in cases where treatment fails or the cancer recurs.
OncoDEEP analyzes 638 carefully selected genes, thereby reducing the costs of individual tests and offering faster results (less than two weeks) to select the most appropriate treatment and act as quickly as possible on advanced cancers.
The OncoDEEP results report can be viewed online on our interactive OncoSHARE platform and downloaded in PDF format for interpretation.